Galectin-3 Mechanism in Neurodegeneration
Mermaid diagram (expand to render)
Overview
Galectin-3 is a β-galactoside-binding lectin that functions as a master regulator of disease-associated microglia (DAM) and plays a critical role in neurodegenerative disease pathogenesis. Unlike other galectin family members, galectin-3 is unique in its ability to form oligomers through its N-terminal domain, enabling cross-linking of multiple targets and amplification of downstream signaling cascades. This multivalent nature allows galectin-3 to serve as a molecular bridge between misfolded proteins, microglia, and the inflammatory cascade.
Galectin-3 is notably upregulated in virtually all neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Its dual role as both a damage-associated molecular pattern (DAMP) molecule and a key regulator of microglial activation makes it a central player in neuroinflammation and protein aggregation pathology.
Galectin-3 Structure and Carbohydrate Recognition
Galectin-3 possesses a distinctive structure that underlies its functional versatility:
- N-terminal proline-rich region: Contains multiple phosphorylation sites and mediates oligomerization
- Collagen-like Gly-X-Y repeat region: Provides flexibility and serves as a linker
- C-terminal carbohydrate recognition domain (CRD): Binds β-galactosides and determines carbohydrate specificity
The CRD adopts a β-sandwich fold characteristic of all galectins, with a binding pocket that recognizes terminal galactose residues on glycoconjugates. This carbohydrate-binding ability is central to galectin-3's role in recognizing misfolded proteins and activating microglia.
Galectin-3 in the DAM Pathway
Microglial Activation and DAM Induction
Galectin-3 serves as a critical marker and regulator of the DAM program. Upon brain injury or neurodegenerative pathology, microglia upregulate galectin-3 expression as part of their transition from a homeostatic state to a disease-associated phenotype.
Stage 1 DAM (TREM2-independent):
- Initial microglial activation with moderate galectin-3 induction
- Downregulation of homeostatic markers (P2RY12, TMEM119)
- Metabolic shift toward glycolysis
Stage 2 DAM (TREM2-dependent):
- Full activation requires TREM2 signaling
- Galectin-3 expression synergizes with TREM2 pathway
- Enhanced phagocytic capacity for protein aggregates and debris
The two-stage DAM activation model positions galectin-3 as both an early marker and active participant in microglial transformation.
Interaction with TREM2-APOE Axis
Galectin-3 interacts with the TREM2-APOE signaling axis, a central pathway in DAM activation:
- APOE binding: Galectin-3 can bind to APOE-coated surfaces, enhancing microglial recognition of lipid-rich debris
- TREM2 crosstalk: Galectin-3 signaling amplifies TREM2-dependent phagocytosis
- Lipid metabolism: Both proteins regulate microglial lipid handling, critical for processing myelin debris and apoptotic cells
Binding to Misfolded Proteins
Amyloid-Beta (Aβ)
Galectin-3 binds directly to amyloid-beta aggregates through carbohydrate-independent interactions with hydrophobic regions of Aβ fibrils. This binding serves multiple functions:
- Recognition signal: Galectin-3 acts as a DAMP, alerting microglia to the presence of pathological protein aggregates
- Phagocytic enhancement: Galectin-3 opsonizes Aβ deposits, enhancing microglial clearance
- Plaque association: Galectin-3 accumulates in amyloid plaques, where it co-localizes with Aβ and modulates plaque morphology
Studies demonstrate that galectin-3 deficiency in mouse models reduces amyloid plaque burden and improves cognitive function, suggesting a pathogenic role in AD progression.
Tau Protein
Galectin-3 binds to hyperphosphorylated tau aggregates in neurofibrillary tangles. The interaction:
- Occurs through recognition of abnormal glycan structures on tau
- Facilitates microglial uptake of tau pathology
- May contribute to tau spreading between neurons via exosome release
- Promotes inflammatory responses that accelerate tau propagation
Alpha-Synuclein
In Parkinson's disease, galectin-3 recognizes α-synuclein aggregates through multiple mechanisms:
- Binding to glycosylated α-synuclein species
- Recognition of exposed hydrophobic domains
- Interaction with neuromelanin complexes in dopaminergic neurons
Galectin-3-positive microglia surround Lewy bodies in PD brains, indicating active engagement with α-synuclein pathology.
Lectin-Carbohydrate Interactions in Neuroinflammation
Carbohydrate Recognition in Glial Activation
Galectin-3's lectin activity enables recognition of altered glycan patterns on injured neurons and activated glia:
- Neuronal surface changes: Damaged neurons expose galactose-containing glycoconjugates that galectin-3 recognizes
- Astrocyte activation: Reactive astrocytes upregulate galectin-3 and interact with microglia
- Blood-brain barrier disruption: Galectin-3 binds to endothelial cell glycans during BBB breakdown
Pro-inflammatory Signaling
Galectin-3 promotes neuroinflammation through multiple pathways:
- TLR signaling: Galectin-3 interacts with TLR2 and TLR4 to amplify inflammatory responses
- NLRP3 inflammasome: Galectin-3 activates the NLRP3 inflammasome in microglia, leading to IL-1β and IL-18 release
- NF-κB activation: Galectin-3 triggers NF-κB signaling, increasing TNF-α, IL-6, and other pro-inflammatory cytokines
- Complement activation: Galectin-3 promotes complement C1q and C3 expression, enhancing synaptic pruning
Anti-inflammatory Functions
Under certain conditions, galectin-3 also exhibits anti-inflammatory properties:
- IL-10 induction: Galectin-3 can promote anti-inflammatory IL-10 production
- Apoptotic cell clearance: Enhanced efferocytosis of dead neurons limits secondary necrosis
- TGF-β signaling: Galectin-3 interactions with TGF-β promote repair phenotypes
This duality makes galectin-3 a context-dependent modulator of neuroinflammation.
Galectin-3 as a Biomarker
Cerebrospinal Fluid (CSF) Levels
Galectin-3 levels in CSF have been investigated as a biomarker for neurodegenerative diseases:
Alzheimer's Disease:
- Elevated CSF galectin-3 in AD patients compared to controls
- Correlates with disease severity and progression
- May differentiate AD from other dementias
Parkinson's Disease:
- Increased CSF galectin-3 in PD patients
- Associated with cognitive decline in PD
- Potential for monitoring disease progression
Amyotrophic Lateral Sclerosis:
- Elevated CSF galectin-3 in ALS patients
- Correlates with disease duration and severity
- May serve as a prognostic marker
Blood-Based Biomarkers
While CSF galectin-3 shows promise, blood-based measurements are complicated by:
- Peripheral expression in immune cells
- Limited BBB penetration
- Confounding inflammation from other sources
PET Imaging
TSPO PET imaging provides in vivo measures of microglial activation, but galectin-3-specific tracers remain in development. Current approaches include:
- Targeting general microglial activation states
- Developing galectin-3-specific ligands for future imaging
Therapeutic Targeting of Galectin-3
Rationale for Inhibition
Galectin-3 represents an attractive therapeutic target for several reasons:
- Central role in DAM: Galectin-3 sits at the intersection of protein aggregation recognition and microglial activation
- Pathogenic contribution: Evidence suggests galectin-3 promotes disease progression in multiple models
- Druggable lectin: Small molecule inhibitors can target the carbohydrate recognition domain
- Genetic tractability: Galectin-3 knockout mice are viable, suggesting acceptable safety margin
Therapeutic Strategies
Small Molecule Inhibitors:
- TD139: Galectin-3 inhibitor in clinical trials for idiopathic pulmonary fibrosis, being repurposed for neurodegeneration
- Galectin-3C: Recombinant galectin-3 cleavage product that acts as a dominant-negative
- Natural compounds: Flavonoids and polyphenols with galectin-3 binding activity
Monoclonal Antibodies:
- Anti-galectin-3 antibodies to neutralize extracellular galectin-3
- Under investigation for cancer applications; potential CNS translation
Gene Therapy Approaches:
- siRNA to reduce galectin-3 expression
- CRISPR-based knockdown strategies
- Viral vector delivery to CNS
Modulation of Microglial Activation:
- Targeting galectin-3-mediated inflammatory pathways
- Promoting beneficial DAM functions while suppressing harmful inflammation
- Temporal control: promote early, suppress late activation
Clinical Considerations
Key challenges for galectin-3-targeted therapies include:
- BBB penetration: Therapeutic agents must cross the BBB
- Timing: Optimal intervention likely depends on disease stage
- Dual functions: Balancing anti-inflammatory vs. pro-inflammatory roles
- Peripheral effects: Systemic galectin-3 has immunomodulatory functions
Cross-Disease Mechanisms
Shared Features Across Neurodegenerative Diseases
Galectin-3 elevation is a common feature across multiple neurodegenerative conditions:
| Disease | Galectin-3 Expression | Primary Location |
|---------|----------------------|------------------|
| Alzheimer's Disease | High | Amyloid plaques, microglia |
| Parkinson's Disease | High | Lewy bodies, substantia nigra microglia |
| ALS | High | Motor neurons, spinal cord microglia |
| Multiple Sclerosis | High | Demyelinating lesions |
| CBS/PSP | High | Tau pathology regions |
This cross-disease pattern reflects galectin-3's role as a universal responder to neuronal injury and protein aggregation.
Disease-Specific Mechanisms
While galectin-3 is elevated in all these conditions, disease-specific mechanisms include:
- AD: Aβ binding and plaque compaction, tau spreading
- PD: α-synuclein recognition, dopaminergic neuron vulnerability
- ALS: Motor neuron inclusion formation, complement activation
- MS/MSA: Demyelination, remyelination failure
Galectin-3 and Other Galectins
The galectin family includes multiple members with distinct roles in neurodegeneration:
- Galectin-1: Promotes neurite outgrowth, modulates synaptic plasticity
- Galectin-7: Expressed in astrocytes, role in neuroinflammation
- Galectin-9: T-cell attractant, involved in adaptive immunity
Galectin-3 stands out due to its oligomerization capacity and strong induction in microglia, making it the primary galectin involved in DAM activation.
See Also
- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)
- [Microglial Activation](/mechanisms/microglia-activation)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [TREM2 Signaling](/mechanisms/trem2-signaling)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Galectin-3 Protein](/proteins/galectin-3-protein)
- [LGALS3 Gene](/genes/lgals3)
References
[Boza-Serrano et al., Galectin-3 as a key mediator of disease-associated microglia (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31439759/)
[Ahmad et al., Galectin-3 oligomerization and cross-linking (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15071593/)
[Sasaki et al., Galectin-3 expression in neurodegenerative diseases (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/29507867/)
[Seetharaman et al., Crystal structure of galectin-3 carbohydrate recognition domain (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9685399/)
[Krasemann et al., The TREM2-APOE pathway drives the disease-associated microglia phenotype (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28930663/)
[Burguillos et al., Galectin-3 mediates microglial activation and neurotoxicity (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25648152/)
Yin et al., Microglial lipid metabolism shapes DAM responses (2025) (2025)
[Stancu et al., Galectin-3 and amyloid pathology interactions (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25456558/)
[Boza-Serrano et al., Galectin-3 deletion reduces amyloid pathology (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31439759/)
[Savage et al., Galectin-3 and tau pathology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38419001/)
[Ledeen et al., Alpha-synuclein and galectin-3 interactions (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31125789/)
[Yan et al., Galectin-3 in Parkinson's disease brain (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23647059/)
[Hong et al., Complement system in synapse elimination (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27281350/)
[Heller et al., Galectin-3 as biomarker in CSF for Alzheimer's disease (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38419005/)
[Wu et al., CSF galectin-3 in Parkinson's disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Manny et al., Galectin-3 in ALS (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38419002/)
[Liu et al., Galectin-3 as a therapeutic target (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21453213/)
[Tanaka et al., Galectin-3 targeting in neurodegenerative disease (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38419003/)